The company gave a sneak peek into its fourth-quarter financial results.
News & Analysis: Esperion Therapeutics
ESPR earnings call for the period ending September 30, 2020.
Sales of these recently launched products could make a big difference for the companies behind them.
ESPR earnings call for the period ending June 30, 2020.
ESPR earnings call for the period ending March 31, 2020.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
Millions of patients who don't respond well enough to statins now have another affordable alternative.
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs it's reviewing this month.
The committee vote puts bempedoic acid on the path for likely approval by the European Medicines Agency.
Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.